Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate, And Sodium Oxybate

Introduction Overview

Generic Name

calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate

Brand Name

Xywav

Dosage Form

oral solution (0.5 g per mL)

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics

Pharmacokinetics

Absorption:
Xywav is administered as an oral solution and is rapidly absorbed from the gastrointestinal tract, with onset of action typically within 5 to 15 minutes after dosing. The absorption can be influenced by food intake; patients are advised to wait at least 2 hours after eating before taking the drug to optimize bioavailability and reduce potential gastric irritation. The active components, collectively oxybate salts, including sodium oxybate (gamma-hydroxybutyrate or GHB), reach systemic circulation promptly, supporting its rapid central nervous system depressant effects.

Distribution:
Following absorption, oxybate salts distribute extensively throughout body tissues. The volume of distribution approximates total body water, reflecting its hydrophilic nature. Due to its small molecular size and ability to cross the blood-brain barrier readily, Xywav acts centrally to exert sedative hypnotic effects. Protein binding is minimal, as GHB and its analogues circulate mostly in free, unbound forms facilitating rapid CNS penetration. There is no evidence of accumulation in fatty tissues.

Metabolism:
Xywav components undergo metabolism primarily via the Krebs (citric acid) cycle. Sodium oxybate and related oxybate salts are metabolized in the liver through enzymatic conversion to succinic semialdehyde and ultimately to carbon dioxide and water. The process offers efficient elimination while producing no active metabolites. The presence of multiple oxybate salts in Xywav (calcium, magnesium, potassium, and sodium) does not significantly alter metabolic pathways compared to sodium oxybate alone. Hepatic metabolism may be influenced by liver function status but no dose adjustment guidelines exist currently.

Elimination:
The metabolites of Xywav are eliminated predominantly as carbon dioxide via exhalation and small amounts excreted in the urine. Less than 5% of the oxybate salts are excreted unchanged in the urine. The elimination half-life of sodium oxybate is approximately 0.5 to 1 hour, supporting the need for two doses per night in many regimens to maintain therapeutic effect. Renal impairment may modestly affect elimination but clinical dosing adjustments have not been definitively established. Due to rapid clearance, steady state is generally reached quickly without prolonged accumulation.

Dosage Forms

Available Dosage Forms:
- Oral solution containing 0.5 grams per milliliter of a fixed combination of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate.
- The solution must be diluted with 2 ounces (1/4 cup) of water prior to dosing, using child-resistant dosing cups provided.

Dosages for Adults and Adolescents:
- Narcolepsy (7 years and older): Initial dose is 4.5 g/day divided into two equal doses (2.25 g each). Dose may be titrated weekly by 1.5 g/day up to a maximum of 9 g/day.
- Idiopathic hypersomnia (≥18 years): Two regimens approved – two times nightly doses starting at 4.5 g/day (2.25 g twice) with titration up to 9 g/day, or once nightly doses starting at 3 g/day with titration up to 6 g/day.
- Dosing requires administration at bedtime and a second dose 2.5 to 4 hours later (if two-dose regimen) with patients remaining in bed after dosing.

Specific Patient Populations:
- Pediatric patients 7 years and older with narcolepsy have weight-based dosing recommendations:
- < 20 kg: Specific dosing not established, generally lower doses used.
- 20 to <30 kg: Start ≤ 2 g/day in two doses; titrate up to 6 g/day max.
- 30 to <45 kg: Start ≤ 3 g/day in two doses; titrate up to 7.5 g/day max.
- ≥ 45 kg: Start ≤ 4.5 g/day in two doses; titrate up to 9 g/day max.
- Use in children <7 years or patients with idiopathic hypersomnia under 18 years is not approved.
- Dosage must be carefully titrated based on efficacy and tolerability, with monitoring for adverse events and treatment response.

Clinical guidelines emphasize that dosing should not be changed or stopped abruptly to avoid withdrawal symptoms, and missed doses should be skipped rather than doubled.

Mechanism Of Action

Xywav acts primarily via its active component sodium oxybate, the sodium salt of gamma-hydroxybutyrate (GHB), a naturally occurring neurotransmitter and metabolite of gamma-aminobutyric acid (GABA) in the central nervous system. The drug exerts its effects by binding to GHB receptors and GABA-B receptors, resulting in modulation of neuronal excitability and neurotransmitter release.

At the molecular level, sodium oxybate interacts with GHB-specific receptors which are coupled to inhibitory G-proteins that decrease intracellular cyclic AMP. Activation of GABA-B receptors leads to postsynaptic hyperpolarization through potassium channel opening and presynaptic inhibition of calcium channels, suppressing excitatory neurotransmitter release. This dual receptor engagement reduces central nervous system excitability, promoting sedative and hypnotic effects.

Clinically, this mechanism improves the quality and quantity of slow-wave, restorative sleep. Enhanced deep sleep phases reduce excessive daytime sleepiness and cataplexy episodes in narcoleptic patients, as well as the profound sleepiness and sleep inertia in idiopathic hypersomnia. Unlike traditional hypnotics that act purely through GABA-A receptors, Xywav’s unique profile may explain its ability to reduce sudden episodes of muscle weakness and improve wakefulness.

Comparatively, sodium oxybate differs from other CNS depressants by its rapid onset and short duration of action, necessitating divided dosing. Research evidence demonstrates significant improvements in subjective and objective measures of sleepiness and cataplexy, supported by pivotal clinical trials such as Study 2 (NCT03533114) for idiopathic hypersomnia, establishing its safety and efficacy profile within controlled settings.

Pharmacological Actions

Central nervous system depressant effect through GHB and GABA-B receptor agonism.
Induction and enhancement of deep slow-wave sleep improving sleep architecture.
Reduction in excessive daytime sleepiness by promoting nocturnal restorative sleep.
Suppression of cataplexy episodes via modulation of neuronal excitability.
Rapid onset action facilitating quick transition to sleep within 5 to 15 minutes.
Minimal active metabolites with metabolism via Krebs cycle, reducing toxicity risk.
Dual receptor activity differentiates Xywav from traditional hypnotics and sedatives.
Potential for physical dependence and psychological addiction due to CNS effects.
Reduction of overnight sleep fragmentation in patients with narcolepsy and idiopathic hypersomnia.
Modulation of neurotransmitter release leading to anxiolytic and sedative properties.
Sodium oxybate component acts as a CNS depressant without narcotic or stimulant properties.
Decreases frequency and severity of cataplexy attacks by restoring normal sleep balance.
Demonstrated improvement in Epworth Sleepiness Scale scores in clinical studies.
Combination of multiple oxybate salts reduces overall sodium load compared to sodium oxybate alone.

Therapeutic Or Clinical Uses

Treatment of cataplexy (sudden loss of muscle strength) in patients aged 7 years and older with narcolepsy.
Reduction of excessive daytime sleepiness (EDS) in narcolepsy patients from 7 years and older.
Treatment of idiopathic hypersomnia (IH) in adults aged 18 years and older.
Improvement of nocturnal sleep quality and quantity in sleep disorders.
Management of sleep fragmentation and restoration of normal sleep architecture.
Reduction in the number and severity of daytime sleeping periods in narcolepsy and IH.
Adjunctive therapy to improve wakefulness and functioning in chronic hypersomnolence disorders.
Off-label use considerations in sleep disorders characterized by excessive daytime fatigue and cataplexy.
Treatment option for patients intolerant or unresponsive to other pharmacologic therapies for narcolepsy symptoms.
Used in patients requiring improved nighttime restorative sleep to mitigate sleep inertia.
Beneficial in patients needing a low-sodium formulation of oxybate for cardiovascular risk reduction.
Employed in complex sleep disorders where central nervous system depressants improve daytime symptoms.
Part of REMS-restricted prescribing program due to abuse potential, ensuring patient safety.
Supports improved quality of life and functional status in narcolepsy and idiopathic hypersomnia.

Side Or Adverse Effects

Sleepwalking, talking, or eating during sleep.
New or worsened sleep problems including strange dreams and night terrors.
Drowsiness, dizziness, and general tiredness.
Headache and tremors.
Anxiety and nervousness.
Dry mouth, nausea, vomiting, and diarrhea.
Decreased appetite.
Increased sweating.
Bedwetting, particularly in pediatric patients.
Respiratory depression including weak or shallow breathing.
Severe drowsiness and light-headedness potentially leading to accidents.
Confusion, hallucinations, paranoia, and unusual thoughts.
Seizures or convulsions.
Depression, suicidal thoughts or actions, and increased emotional lability.
Sleepwalking-related injuries due to impaired awareness.
Potential for physical dependence and withdrawal symptoms on abrupt discontinuation.
Allergic reactions including hives, swelling of face, lips, tongue, or throat requiring emergency care.

Precautions

Avoid concurrent use with alcohol due to risk of fatal respiratory depression.
Do not combine with other sedatives, hypnotics, or CNS depressants.
Use cautiously in patients with a history of respiratory problems or sleep apnea.
Monitor patients closely for emerging or worsening depression and suicidality.
Avoid abrupt discontinuation to prevent withdrawal symptoms; taper dose under medical supervision.
Exercise caution in patients with liver disease due to metabolic considerations.
Pregnancy and breastfeeding safety not established; weigh benefits and risks carefully.
Keep medication out of reach of others to prevent misuse, abuse, or accidental ingestion.
Educate patients on risks of sleepwalking and performing activities while not fully awake.
Avoid hazardous activities requiring full alertness for at least 6 hours post-dose.
Use only under Xywav REMS program and certified prescriber/pharmacist oversight.
Do not use in patients with succinic semialdehyde dehydrogenase deficiency.
Patients with substance use disorder require careful assessment before initiation.
Instruct on proper dilution and timing of doses to ensure safe administration.
Careful dosing required in pediatric patients to prevent overdose and adverse effects.

Warnings

Potential for severe drowsiness and respiratory depression even at prescribed doses.
Fatal outcomes possible if combined with alcohol or other CNS depressants.
Risk of addiction, overdose, and death from misuse or abuse.
Contains sodium oxybate, a substance with known potential for abuse.
Must be dispensed only through Xywav REMS restricted distribution program.
Misuse can lead to seizures, loss of consciousness, respiratory arrest, or death.
Sleepwalking and related behaviors can cause serious injury.
May cause confusion, anxiety, paranoia, hallucinations, or psychosis.
Risk of suicidal ideation or behavior; monitoring required.
Not approved for use in children under 7 years for narcolepsy or under 18 for idiopathic hypersomnia.
Do not drive, operate machinery, or perform hazardous activities until fully alert.
Abrupt discontinuation may cause unpleasant withdrawal symptoms.
Keep out of reach of children and individuals with substance abuse history.
Selling or distributing the drug is illegal and can harm others.
Pregnancy and breastfeeding safety have not been established, potential risks unknown.

Contraindication

Known hypersensitivity to calcium oxybate, magnesium oxybate, potassium oxybate, sodium oxybate, or any formulation components.
Patients with succinic semialdehyde dehydrogenase deficiency.
Concomitant use with alcohol or other CNS depressants that increase risk of respiratory depression.
Severe respiratory compromise or untreated sleep apnea.
Use in children under 7 years of age for narcolepsy and under 18 years for idiopathic hypersomnia.
History of hypersensitivity reactions or anaphylaxis to sodium oxybate or related compounds.
Patients unable to comply with REMS requirements and safe dosing procedures.
Situations where patient supervision and adherence to dosing schedule are not feasible.

Drug Interactions

Additive CNS depressant effects with benzodiazepines, opioids, barbiturates, and alcohol.
Potentially fatal respiratory depression with concurrent use of other sedatives or hypnotics.
Divalproex (Depakote) may affect oxybate metabolism requiring dose adjustment.
Caution with medications affecting GABAergic neurotransmission, including certain antiepileptics.
Interactions with muscle relaxants may enhance sedation and respiratory depression.
Non-prescription cold and allergy medications with sedative properties can increase CNS depression.
Antidepressants and anxiolytics may interact pharmacodynamically leading to enhanced side effects.
Vitamins and herbal supplements containing CNS active ingredients should be used cautiously.
Concurrent use of seizure medications may require monitoring for altered efficacy or toxicity.
Additive hypotensive effects possible with some antihypertensive agents.
Potential interference with neuropsychological drugs altering mental status and mood.
No significant pharmacokinetic interactions with electrolytes despite multiple oxybate salts.
Interactions can result in increased risk of sedation, respiratory difficulties, or cognitive impairment.
Patients should disclose all medications and supplements to healthcare providers prior to Xywav initiation.
Dose adjustments and careful monitoring required when starting or stopping interacting drugs.

Preparations Of The Drug

Xywav oral solution containing a fixed combination of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate at 0.5 g/mL concentration.
Supplied as a clear liquid requiring dilution with water before administration.
Packaged with child-resistant dosing cups to ensure accurate measuring and patient safety.
Dispensed in tight containers protecting from moisture and contamination.
Diluted solutions should be consumed within 24 hours to maintain potency and safety.
Requires storage at controlled room temperature (20°C to 25°C or 68°F to 77°F).
Shelf-life and stability data support single batch preparation with discard of unused solution post 24 hours.
Inclusion of sucralose as a sweetener to improve palatability.
Comprehensive REMS program materials accompany each prescription including patient guides and counseling checklists.
Specialized prescription forms mandated at treatment initiation and after prolonged treatment interruption.
Not available as tablets, capsules, or injectable forms.
Formulation designed to minimize sodium load compared to older sodium oxybate formulations.
Dosing cups calibrated to facilitate dosing flexibility for pediatric and adult patients.
Available exclusively through certified pharmacies participating in the Xywav REMS program.
Packaging includes detailed instructions for dilution, administration, and disposal to prevent misuse.